• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

    9/26/24 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email

    Teleconference and Webcast to be held on October 1, 2024

    CRANBURY, N.J., Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1, 2024, before the open of the U.S. financial markets.

    Palatin Technologies, Inc.

    Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on October 1, 2024 at 11:00 AM Eastern Time. The conference call will include a review of the company's operating results and an update on programs under development.

    Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

    Q4 & Fiscal Year End 2024 Results Press Release                 

    10/01/2024 at 7:30 a.m. ET





    Q4 & Fiscal Year End 2024 Conference Call-Live               

    10/01/2024 at 11:00 a.m. ET

       US Toll Free Dial-In Number:                                        

    1-888-506-0062

       International Dial-In Number:                                        

    1-973-528-0011

       Participant Access Code:                                                 

    252326





    Q4 & Fiscal Year End 2024 Conference Call-Replay              

    10/01/2024-10/15/2024

       US Toll Free Dial-In Number:                                          

    1-877-481-4010

       International Dial-In Number:                                         

    1-919-882-2331

       Participant Access Code:                                              

    51290

    The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

    About Palatin

    Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-fourth-quarter-and-fiscal-year-end-2024-results-302259586.html

    SOURCE Palatin Technologies, Inc.

    Get the next $PTN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      5/12/25 9:30:59 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      4/11/24 4:45:17 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care